Showing 1 to 3 of 3 results


PromarkerEso Blood Test Shows High Accuracy in Detecting Oesophageal Cancer
Proteomics International Laboratories' PromarkerEso blood test for oesophageal cancer showed 91.4% accuracy in detecting the cancer and 98.9% accuracy in identifying those without it in a 259-person study, exceeding the accuracy of existing tests and paving the way for commercial release.
PromarkerEso Blood Test Shows High Accuracy in Detecting Oesophageal Cancer
Proteomics International Laboratories' PromarkerEso blood test for oesophageal cancer showed 91.4% accuracy in detecting the cancer and 98.9% accuracy in identifying those without it in a 259-person study, exceeding the accuracy of existing tests and paving the way for commercial release.
Progress
56% Bias Score


Chinese Patent Granted for Proteomics' Muscle Stress Test
OxiDx Limited, a 66 percent-owned subsidiary of ASX-listed Proteomics International Laboratories, secured a Chinese patent for its muscle stress test, a rapid, low-cost blood test detecting muscle damage caused by oxidative stress, impacting athletes, racehorses, and general health.
Chinese Patent Granted for Proteomics' Muscle Stress Test
OxiDx Limited, a 66 percent-owned subsidiary of ASX-listed Proteomics International Laboratories, secured a Chinese patent for its muscle stress test, a rapid, low-cost blood test detecting muscle damage caused by oxidative stress, impacting athletes, racehorses, and general health.
Progress
52% Bias Score

Proteomics to Launch Highly Accurate Endometriosis Blood Test
Proteomics International Laboratories will commercially launch PromarkerEndo, a highly accurate blood test for endometriosis, in Australia during the third quarter of 2024, using a 'traffic light' risk assessment system to improve early diagnosis and reduce the current seven-year average delay.

Proteomics to Launch Highly Accurate Endometriosis Blood Test
Proteomics International Laboratories will commercially launch PromarkerEndo, a highly accurate blood test for endometriosis, in Australia during the third quarter of 2024, using a 'traffic light' risk assessment system to improve early diagnosis and reduce the current seven-year average delay.
Progress
64% Bias Score
Showing 1 to 3 of 3 results